These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14656689)

  • 1. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
    Lampasona V; Rio J; Franciotta D; Furlan R; Avolio C; Fazio R; Lavolpe V; Vincent A; Comi G; Trojano M; Montalban X; Martino G
    Eur Cytokine Netw; 2003; 14(3):154-7. PubMed ID: 14656689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
    Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
    J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
    Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
    Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against interferon-beta in multiple sclerosis.
    Aarskog NK; Marøy T; Myhr KM; Vedeler CA
    J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C; Gibassier J; Oger J; Le Page E; Edan G
    Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.
    Lawrence N; Oger J; Aziz T; Palace J; Vincent A
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1236-9. PubMed ID: 12933925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
    Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M
    J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients.
    Di Marco P; Pagnotti P; Bellomi F; De Vito G; Sessa E; Bagnato F; Scagnolari C; Bramanti P; Antonelli G
    New Microbiol; 2006 Jan; 29(1):11-8. PubMed ID: 16608120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS; Rice GP; Alsop JC;
    Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
    Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
    J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.
    Ross C; Clemmesen KM; Svenson M; Sørensen PS; Koch-Henriksen N; Skovgaard GL; Bendtzen K
    Ann Neurol; 2000 Nov; 48(5):706-12. PubMed ID: 11079533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.